Pharmaceuticals

Takeda Singapore receives coveted HR accolades by creating an exceptional people experience

Key points: * Takeda Singapore receives Great Place to Work® award for the first time and Top Employer certification for the sixth consecutive year. * A significant majority of employees surveyed in Singapore in 2021 Great Place to Work® Trust Index stated that Takeda is a great workplace. ...

2022-05-09 09:00 2132

InxMed Raised $15 million in Series B+ Financing to Advance Innovative Therapies to Drug-resistant Cancers

NANJING, China, May 8, 2022 /PRNewswire/ -- InxMed Co., Ltd, a clinical-stage biotechnology company dedicated to developing innovative therapies targeting stroma microenvironment and drug resistance for hard-to-treat solid tumors, today announced that it had completed $15 million in Series B+ Fin...

2022-05-09 08:04 1852

ExoCoBio Receives Japanese Patent for Alleviating Dermatitis with Adipose Stem Cell-Derived Exosome

* To lay a technological foundation for developing exosome-based medicines and cosmetic products for dermatitis treatment * To prove the technological feasibility of ExoSCRT™ for the mass-production of the world's best exosomes with high efficacy SEOUL, Korea, May 9, 2022 /PRNewswire/ -- ExoC...

2022-05-09 07:00 3526

Brii Bio Reports Progress on ESG Commitments in Its Inaugural ESG Report

DURHAM, N.C. and BEIJING, May 7, 2022 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company," stock code: 2137.HK), a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public health...

2022-05-07 09:00 5314

Antengene to Participate in Three Upcoming Investor Conferences in May/June

CICC Healthcare Industry Forum 2022: May 9th to 12th BTIG Virtual China Biotech Day: June 1st Citi's 3rd Pan-Asia Regional Investor Conference 2022: June 8th to June 10th SHANGHAI and HONG KONG, May 6, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading inno...

2022-05-06 08:30 2816

Harbour BioMed Appoints Dr. Alexander A. Zukiwski to its Scientific Advisory Board

CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, May 5, 2022 /PRNewswire/ -- Harbour BioMed ("HBM", HKEX:02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics, is pleased to announce the appointment o...

2022-05-06 08:00 2090

Insilico Medicine expands synthetic lethality portfolio with the nomination of a preclinical candidate targeting MAT2A for the treatment of MTAP-deleted cancers

NEW YORK, May 6, 2022 /PRNewswire/ -- Insilico Medicine ("Insilico"), a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, today announced that the company has nominated a preclinical candidate (PCC) targeting methionine adenosyltransferase 2A (MAT2A) from AI-de...

2022-05-06 05:00 2843

Insilico Medicine expands synthetic lethality portfolio with nomination of a preclinical candidate targeting MAT2A for the treatment of MTAP-deleted cancers

NEW YORK, May 5, 2022 /PRNewswire/ -- Insilico Medicine ("Insilico"), a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, today announced that the company has nominated a preclinical candidate (PCC) targeting methionine adenosyltransferase 2A (MAT2A) from AI-de...

2022-05-05 23:00 2874

HOYA Vision Care Releases Results of First of its Kind Six-Year MiYOSMART Spectacle Lens Follow-up Clinical Study

Strong evidence shows continued long-term lens effectiveness in slowing myopia progression in children BANGKOK, May 5, 2022 /PRNewswire/ -- HOYA Vision Care, a leader in optical technology innovation, shared the results of asix-year follow-up clinical study on its award winning MiYOSMART spectac...

2022-05-05 22:12 3787

Daewoong Pharmaceutical announced first-quarter 2022 results

- Marked sales of KRW 272.2 billion and operating profit of KRW 26.8 billion - Reported record-high quarterly operating profit, thanks to highly profitable ETC drugs and export growth of Nabota - Expected to see increasing profitability and robust growth due to export expansion of Nabota and the...

2022-05-05 21:00 2017

TIKOMED and IQVIA announce a strategic collaboration for the development of TIKOMED's lead drug platform candidate ILB®

VIKEN, Sweden, May 5, 2022 /PRNewswire/ -- Today, Swedish biopharmaceutical company TikoMed AB and IQVIA announce a key strategic collaboration with the aim to accelerate the development of TikoMed's lead drug platform candidate ILB®, a broad-spectrum small molecule drug candidate with curative p...

2022-05-05 20:40 1577

I-Mab Provides Updates on Status under Holding Foreign Companies Accountable Act

SHANGHAI and GAITHERSBURG, Md., May 5, 2022 /PRNewswire/ -- I-Mab ("I-Mab" or the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today provided updates on its status under the Holding Foreign...

2022-05-05 20:00 1671

111, Inc. Provides Updates on its Status Under the Holding Foreign Companies Accountable Act

SHANGHAI, May 5, 2022 /PRNewswire/ -- 111 Inc. ( "111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company inChina, today announced that onMay 4th, 2022, the Securities and Exchange Commission (the "SEC") provisionally listed the Company as a "Commission-Identified ...

2022-05-05 17:18 1792

Clinical Trial Approval For ReCOV In The PRC And The Overseas Clinical Trial Progress Of ReCOV

TAIZHOU, China, May 5, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the"Company", together with its subsidiaries, the "Group",Stock code:2179.HK) is pleased to announce that the Company has recently received the clinical trial approval (the "Clinical Trial Approval") for its recombin...

2022-05-05 11:55 2985

First Patient Dosed in Phase II Renal Cancer Theranostics Study

MELBOURNE, Australia and INDIANAPOLIS, May 5, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that a first patient has been dosed in the 'STARLITE 2' Phase II study of the Company's investigational renal cancer therapy, TLX250 (177 Lu-DOTA-girentu...

2022-05-05 05:00 2435

Kintor Pharma Announces First Patient Dosing in Multi-Regional Global Phase II Clinical Trial of ALK-1 Antibody and Nivolumab Combination Therapy for the Treatment of Advanced Hepatocellular Carcinoma

SUZHOU, China, May 4, 2022 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma," HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced the first patient dosing inthe United States of its multi-regional pha...

2022-05-04 20:36 2356

Juniper Biologics signs exclusive license agreement with Helsinn for infigratinib (INN) for the emerging markets*

LUGANO, Switzerland, and SINGAPORE, May 4, 2022 /PRNewswire/ -- Juniper Biologics Pte Ltd, a science-led healthcare company focused on researching, developing and commercializing novel therapies, and Helsinn Group, a fully integrated, global biopharma company with a diversified pipeline of innova...

2022-05-04 14:00 2228

China Mobile Hong Kong Launches Online Medical App "Dr. HK"

Four Major Features Providing Doctor Consultation and Prescription While Staying at Home Medicine Doorstep Delivery in 4 hours at the earliest Free of Charge Video Consultation, Medication and Delivery for First 500 Users HONG KONG, May 4, 2022 /PRNewswire/ -- With the rise of the digital lifest...

2022-05-04 12:00 4633

United Imaging Flips the Script on its Events Program for 2022, Reveals Expanded Sales Force and U.S. Growth

Its new AE University also  trains new salespeople on the company's unique take on medical imaging purchasing. HOUSTON, May 3, 2022 /PRNewswire/ -- United Imaging, a global leader in advanced medical imaging and radiotherapy equipment, said that it has enhanced its U.S. domestic events progr...

2022-05-03 23:22 2005

Servatus strengthens Board with appointment of biopharmaceutical division head at Boehringer Ingelheim, Dr Uwe Buecheler

* New Board appointment deepens and consolidates Servatus' extensive commercial and scientific expertise for its global biotherapeutics programs * Dr Buecheler joins as Non-Executive Director from leading pharmaceutical giant Boehringer Ingelheim inGermany, where he is both Senior Vice Preside...

2022-05-02 07:36 3475
1 ... 185186187188189190191 ... 320

Week's Top Stories